Skip to main content
SpringerLink
Log in

Liver Neuroendocrine Metastases Laser Ablation

  • Chapter
  • First Online:
Book cover Image-guided Laser Ablation

  • 497 Accesses

Abstract

Liver metastases are frequently present at the initial diagnosis of neuroendocrine neoplasms, or occur in the course of the disease, also in slow-growing tumors. Systemic treatments often obtain disease stabilization, but they rarely achieve objective radiological response. Conversely, an aggressive cytoreduction of at least 70% of tumor burden with liver-directed approach can positively impact on both survival and hormonal symptom control, in particular in patients with indolent disease progression, or disease stabilized by systemic therapies. To this aim, surgical resection, transarterial embolization and chemoembolization, selective internal radiation therapy with yttrium-90 microspheres, and image-guided thermal ablation can be profitably used sequentially or in combination with each other according to tumor and patient characteristics. Among the ablative techniques, at present radiofrequency ablation is the most experienced and used modality to treat liver metastases from neuroendocrine neoplasms, but laser ablation with the multifiber technique presents some peculiarities that could make it the ablative technique of choice in the next future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1–18.

    Article  Google Scholar 

  2. Mocellin S, Nitti D. Gastrointestinal carcinoid. Epidemiological and survival evidence from a large population-based study (n 25 531). Ann Oncol. 2013;24:3040–4.

    Article  CAS  Google Scholar 

  3. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934–43.

    Article  CAS  Google Scholar 

  4. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System (ed 4). Lyon, International Agency for Research on Cancer. 2010.

    Google Scholar 

  5. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  Google Scholar 

  6. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404–7.

    Article  CAS  Google Scholar 

  7. American Joint Committee on Cancer (AJCC). AJCC cancer staging handbook: from the ajcc cancer staging manual. 7th ed. New York: Springer; 2010.

    Book  Google Scholar 

  8. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7:865–8.

    Article  CAS  Google Scholar 

  9. Bosman FT, Carneiro F, Hruban RH, et al. World Health Organization classification of tumors. In: Pathology and genetics. Tumors of the digestive system. Lyon: IARC Press; 2010.

    Google Scholar 

  10. Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.

    Article  CAS  Google Scholar 

  11. Fairweather M, Swanson R, Wang J, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319–25.

    Article  Google Scholar 

  12. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201–7.

    Article  Google Scholar 

  13. Elias D, Goerè D, Leroux G, et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol. 2009;35:1092–7.

    Article  CAS  Google Scholar 

  14. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2014;30:435–41.

    Article  Google Scholar 

  15. Kolbec KJ, Farsad K. Catheter-based treatments for hepatic metastases from neuroendocrine tumors. Am J Roentgenol. 2014;203:717–24.

    Article  Google Scholar 

  16. Cavalcoli F, Rausa E, Conte D, et al. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol. 2017;23(15):2640–50.

    Article  Google Scholar 

  17. Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors. Consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715–31.

    Article  Google Scholar 

  18. Öberg K, Knigge U, Kwekkeboom D, Perren A. ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):124–30.

    Google Scholar 

  19. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77.

    Article  Google Scholar 

  20. Kulke MH, Benson AB, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Cancer Netw. 2012;10(6):724–64.

    Article  CAS  Google Scholar 

  21. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.

    Article  Google Scholar 

  22. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–36.

    Article  Google Scholar 

  23. Oberg K, Astrup L, Eriksson B, Nordic NE Tumour Group. et al. Guidelines for management of gastropancreatic neuroendocrine tumours. Acta Oncol. 2004;43:617–25.

    Article  Google Scholar 

  24. Ramage JK, Davies AH, Ardill J. UKNETwork for Neuroendocrine Tumours et al.. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1–iv16.

    PubMed  PubMed Central  Google Scholar 

  25. Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncology. 2009;100:635–8.

    Article  Google Scholar 

  26. Maxwell JE, Sherman SK, O’Dorisio TM, et al. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159:320–33.

    Article  Google Scholar 

  27. Chambers AJ, Pasieka JL, Dixon E, et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144:645–51.

    Article  Google Scholar 

  28. Graff-Baker AN, Sauer DA, Pommier SJ, et al. Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients. Surgery. 2014;156:1369–76.

    Article  Google Scholar 

  29. Gomez D, Malik HZ, Al-Muktar KV, et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB. 2007;9:345–51.

    Article  CAS  Google Scholar 

  30. Amersi FF, McElrath-Garza A, et al. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg. 2016;141:581–7.

    Article  Google Scholar 

  31. Taner T, Atwell TD, Zhang L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB. 15:190–5.

    Article  Google Scholar 

  32. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10–9.

    Article  Google Scholar 

  33. Mohan H, Nicholson P, Winter DC, et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol. 2015;26:935–42.

    Article  Google Scholar 

  34. Akyildiz HY, Mitchell J, Milas M, et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-ups. Surgery. 2010;148:1288–93.

    Article  Google Scholar 

  35. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8–12.

    Article  CAS  Google Scholar 

  36. Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. Am J Roentgenol. 2003;181:1005–10.

    Article  Google Scholar 

  37. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985–90.

    Article  Google Scholar 

  38. Hellman P, Ladjevardi S, Skogseid B, et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26:1052–6.

    Article  Google Scholar 

  39. Elvin A, Skogseid B, Hellman P. Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging. 2005;30:427–34.

    Article  CAS  Google Scholar 

  40. Qian GJ, Wang N, Shen Q, et al. Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol. 2012;22:1983–90.

    Article  Google Scholar 

  41. Cavagnaro M, Amabile C, Bernardi P, et al. A minimally invasive antenna for microwave ablation therapies: design, performances, and experimental assessment. IEEE Trans Biomed Eng. 2011;58:949–59.

    Article  Google Scholar 

  42. Di Vece F, Tombesi P, Ermili F, et al. Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot study. Cardiovasc Intervent Radiol. 2014;37:723–9.

    PubMed  Google Scholar 

  43. Martin RCG, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–8.

    Article  Google Scholar 

  44. Wang W, Seeruttun SR, Fang C, Zhou Z. Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. Chin J Cancer Res. 2014;26(4):501–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  45. Pacella CM, Bizzarri G, Magnolfi F, Cecconi P, Caspani B, Anelli V, et al. Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients. Radiology. 2001;221:712–20.

    Article  CAS  Google Scholar 

  46. Di Costanzo GG, D’Adamo G, Tortora R, Zanfardino F, Mattera S, Francica G, et al. A novel needle guide system to perform percutaneous laser ablation of liver tumors using the multifiber technique. Acta Radiol. 2013;54:876–81.

    Article  Google Scholar 

  47. Tombesi P, Di Vece F, Sartori S. Radiofrequency, microwave, and laser ablation of liver tumors: time to move toward a tailored ablation technique? Hepatoma Res. 2015;1:52–7.

    Article  CAS  Google Scholar 

  48. Sartori S, Di Vece F, Ermili F, Tombesi P. Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave? World J Radiol. 2017;9:91–6.

    Article  Google Scholar 

  49. Sartori S, Di Vece F, Bianchi L, Tombesi P. Percutaneous laser thermal ablation in a patient with 22 liver metastases from pancreatic neuroendocrine tumor. A case report. EMJ Hepatol. 2018;6(1):95–9.

    Google Scholar 

  50. Tombesi P, Di Vece F, Sartori S. Laser ablation for hepatic metastases from neuroendocrine tumors. AJR Am J Roentgenol. 2015;204:W 732.

    Article  Google Scholar 

  51. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Intervent Radiol. 2014;25:1691–705.. e4

    Article  Google Scholar 

  52. Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6.

    Article  CAS  Google Scholar 

  53. Sartori S, Tombesi P, Di Vece F. Laser thermal ablation in multimodality treatment of liver metastases from neuroendocrine tumors. Echolaser News. 2014;6(Sept):1–3.

    Google Scholar 

  54. Pacella CM, Nasoni S, Grimaldi F, et al. Laser ablation with or without chemoembolization for unresectable neuroendocrine liver metastases: a pilot study. Int J Endo Oncol. 2016. doi:https://doi.org/10.2217/ije.15.34.

    Article  CAS  Google Scholar 

  55. Vogl TJ, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol. 2009;193(4):941–7.

    Article  Google Scholar 

  56. Sartori S, Tombesi P, Macario F, Nielsen I, Tassinari D, Catellani M, Abbasciano V. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. Radiology. 2008;248:670–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Interventional Ultrasound, St. Anna Hospital, Ferrara, Italy

    Sergio Sartori, Francesca Di Vece & Paola Tombesi

  2. Department of Diagnostic Imaging and Interventional Radiology, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy

    Claudio Maurizio Pacella

Authors
  1. Sergio Sartori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Di Vece
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Tombesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudio Maurizio Pacella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Sartori .

Editor information

Editors and Affiliations

  1. Department of Interventional Radiology, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy

    Claudio Maurizio Pacella

  2. Department of Ultrasound, Zhejiang University, Hangzhou, China

    Tian'an Jiang

  3. Division of Interventional Radiology, European Institute of Oncology, IRCCS, Milan, Italy

    Giovanni Mauri

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sartori, S., Di Vece, F., Tombesi, P., Pacella, C.M. (2020). Liver Neuroendocrine Metastases Laser Ablation. In: Pacella, C., Jiang, T., Mauri, G. (eds) Image-guided Laser Ablation. Springer, Cham. https://doi.org/10.1007/978-3-030-21748-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-21748-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-21747-1

  • Online ISBN: 978-3-030-21748-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation